Simultaneous monitoring of argatroban and its major metabolite using an HPLC method: Potential clinical applications

Clinical and Applied Thrombosis/Hemostasis

Volumn 5, Issue 4, 1999, Pages 252-258

  Ahmad, Sarfraz ^a   Ahsan, Ahmad ^a   George, Magdalena ^a   Iqbal, Omer ^a   Jeske, Walter P ^a   McKenna, Rajalaxmi ^a   Lewis, Bruce E ^a   Walenga, Jeanine M ^a   Fareed, Jawed ^a,b  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

^b LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Antithrombin drugs; Argatroban; Heparin induced thrombocytopenia; HPLC; M1 metabolite

Indexed keywords

ARGATROBAN; DRUG METABOLITE; HEPARIN;

ANTICOAGULATION; ARTICLE; BLEEDING; CORONARY ARTERY DILATATION; DRUG DETERMINATION; DRUG INDICATION; DRUG METABOLISM; DRUG STRUCTURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; KIDNEY FUNCTION; LIVER FUNCTION; PRIORITY JOURNAL; THROMBOCYTOPENIA;

EID: 0032727438     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/107602969900500409     Document Type: Article

References (16)

1. Walenga JM, Jeske WP, Wood JJ, et al. Laboratory tests for heparin-induced thrombocytopenia: A multicenter study. Semin Hematol 1999;36(Suppl. 1):22.
2. Jang IK, Giugliano RP, Massey TJ, Schwarz RP Jr. A randomized, blinded study of two doses of Novastan (brand of argatroban) versus heparin as adjunctive therapy to recombinant tissue plasminogen activator (accelerated administration) in acute myocardial infarction: rationale and design of the myocardial infarction using Novastan and t-PA (MINT) study. J Thromb Thrombolysis 1998; 5:49.
3. Weitz JI, Hirsh J. New anticoagulant strategies. J Lab Clin Med 1993;122:364.
4. Lewis BE, Walenga JM, Wallis DE. Anticoagulation with Novastan (argatroban) in patients with heparin-induced thrombocytopenia and heparin-induced thrombocytopenia with thrombosis syndrome. Semin Thromb Hemost 1997;23:197.
5. Berry CN, Girardot C, Lecoffre C, Lunven C. Effects of the synthetic thrombin inhibitor argatroban on fibrin- or clot-incorporated thrombin: comparison with heparin and recombinant hirudin. Thromb Haemost 1994;72:381.
6. Ahmad S, Ahsan A, Iqbal O, et al. Pharmacokinetics and pharmacodynamics of a synthetic antithrombin agent, argatroban, in man as studied by HPLC and functional methods: implications in the monitoring and dosage optimizations in cardiovascular patients. Clin Appl Thromb Hemost 1998;4:243.
7. Fitzgerald D, Murphy N. Argatroban: a synthetic thrombin inhibitor of low relative molecular mass. Coron Artery Dis 1996;7:455.
8. Banner DW, Hadvaly P. Crystallographic analysis at 3.0-A° resolution of the binding to human thrombin of four active-site directed inhibitors. J Biol Chem 1991;266:20085.
9. Data on file, Texas Biotechnology Corporation, Houston, TX.
10. Okamoto S, Hijikata A, Kikimoto R, et al. Potent inhibition of thrombin by the newly synthesized arginine derivatives No. 805. The importance of stereo structure of its 'hydrophobic carboxamide portion. Biochem Biophys Res Commun 1981;101:440.
11. Callas DD, Hoppensteadt D, Fareed J. Comparative studies on the anticoagulant and protease generation inhibitors actions of newly developed site-directed thrombin inhibitory drugs. Efegatran, argatroban, hirulog and hirudin. Semin Thromb Hemost 1995;21:1.
12. Ahmad S, Ahsan A, Iqbal O, et al. Simultaneous monitoring of argatroban and its major metabolite using an HPLC method: potential clinical applications. Ann Hematol 1999;78:A67.
13. Topol EJ, Bonan R, Jewitt D, et al. Use of a direct antithrombotic inhibitor, hirulog, in place of heparin during coronary angioplasty Circulation 1993;87:1622.
14. Topol EJ. Novel antithrombotic approaches to coronary artery disease. Am J Cardiol 1995;75:27B.
15. Jeske WP, Walenga JM, Lewis BE, Fareed J. Pharmacology of argatroban. Exp Opin Invest Drugs 1999;8:625.
16. Clarke RJ, Mayo J, FitzGerald GA, FitzGerald DJ. Combined administration of aspirin and a specific thrombin inhibitor in man. Circulation 1991;83:1510.